Pricing Log in Create free account
Sunday 11 October 2026 Export all PFE data to Excel Powerpack

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

28.28 0.46 +1.65%
Market cap
$158.6B
P/E
37.2×
Fwd P/E
12.2×
Dividend yield
6.08%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Pfizer Inc. 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 12:44 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 27, 2025: 35 added · 24 removed · 77 modified; 21 with only figures updated

  1. Modified · split · ABOUT PFIZER

    Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on June 2, 1942.

135 more changes in this Item, word by word, in Powerpack.

Powerpack